lunes, 31 de marzo de 2014

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer — NEJM

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer — NEJM



ORIGINAL ARTICLE

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, M.D., Ph.D., Dong-Wan Kim, M.D., Ph.D., Ranee Mehra, M.D., Daniel S.W. Tan, M.B., B.S., Enriqueta Felip, M.D., Ph.D., Laura Q.M. Chow, M.D., D. Ross Camidge, M.D., Ph.D., Johan Vansteenkiste, M.D., Ph.D., Sunil Sharma, M.D., Tommaso De Pas, M.D., Gregory J. Riely, M.D., Ph.D., Benjamin J. Solomon, M.B., B.S., Ph.D., Juergen Wolf, M.D., Ph.D., Michael Thomas, M.D., Martin Schuler, M.D., Geoffrey Liu, M.D., Armando Santoro, M.D., Yvonne Y. Lau, Ph.D., Meredith Goldwasser, Sc.D., Anthony L. Boral, M.D., Ph.D., and Jeffrey A. Engelman, M.D., Ph.D.
N Engl J Med 2014; 370:1189-1197March 27, 2014DOI: 10.1056/NEJMoa1311107
 Comments open through April 2, 2014
Abstract
Article
References
Citing Articles (1)
Comments

CITING ARTICLES

  1. 1
    Thomas , Roman K. , . (2014) Overcoming Drug Resistance in ALK-Rearranged Lung Cancer. New England Journal of Medicine 370:13, 1250-1251
    Full Text

No hay comentarios:

Publicar un comentario